



Reduction of share capital

In reference to company announcement no. 14/2020, Novozymes has now registered the final implementation of the reduction of its shares with the Danish Business Authority. The nominal value of the reduction is DKK 12,000,000 equaling a cancellation of 6,000,000 B shares held in Novozymes' treasury, at a nominal value of DKK 2 each. Consequently, the reduction of Novozymes' B shares from DKK 474,512,800 to DKK 462,512,800 has been completed.

Following the above, and pursuant to Article 32 of the Danish Capital Markets Act, Novozymes hereby announces that its total shares as of today consists of nominally DKK 570,000,000, equaling 285,000,000 shares, divided into 53,743,600 A shares and 231,256,400 B shares with a nominal value of DKK 2 each and a total of 1,537,384,800 voting rights.

	Nominal Value, DKK	Number of shares
A shares	107,487,200	53,743,600
B shares	462,512,800	231,256,400
Total	570,000,000	285,000,000

On March 27, 2020, following the reduction of its shares, Novozymes held 3,268,142 million B shares in treasury, equivalent to 1.1% of the reduced total share capital.

March 27, 2020

Company announcement No. 20

Contact information

novozymesIR@novozymes.com

Tobias Cornelius Björklund
+45 3077 8682
tobb@novozymes.com

Carl Ahlgren
+1 919 702 6144
cxal@novozymes.com

Ulrik Wu Svare
+45 3077 3187
ulms@novozymes.com

About Novozymes

Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.novozymes.com

Novozymes A/S CVR number: 10 00 71 27 LEI: 529900T6WNZXD2R3JW38

Novozymes A/S

Krogshøjvej 36
2880 Bagsvaerd
Denmark

Phone: +45 4446 0000

Rethink Tomorrow

novozymes 